Insider buying last 90 days
No open-market insider purchases were filed for NVO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NVO insider filing, plotted on the chart in Gekko.Open NVO in Gekko
Novo Nordisk (NVO) Stock Analysis & Forecast
$43.24+0.05 (+0.1%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryNovo Nordisk closes at $43.24, below both its 50-day average of $46.90 and 200-day average of $46.15. The GekkoIndex reads 64.7, placing the stock in the Accumulation zone. Price sits 27.1% below Gekko Fair Value of $59.34, a gap that bears watching. Over the past month the stock is down 7%, while the six-month return stands at 16.6% and the one-year return at -25.7%.
This week's news centers on regulatory and partnership activity alongside competitive pressure. The CHMP issued a positive opinion for denecimig in hemophilia A, with flexible dosing and a potential 2026 launch, following an EMA committee endorsement described as part of broader pipeline advances. Novo also expanded its AI push through a deal with Anthropic aimed at drug discovery, and signed an agreement with Orbis Medicines worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases. Separately, coverage noted a 5% weekly decline tied to intensifying GLP-1 competition and semaglutide-related risks, with commentary contrasting Novo's position against Eli Lilly amid broader GLP-1 demand trends.
Looking ahead, the next earnings date falls on 4 November, 45 days out and beyond a typical 20-trading-day hold. Over the last 90 days, Congress recorded 1 buy and 0 sells. Analyst coverage from 6 firms shows 5 hold ratings and 1 sell, with a consensus target of $46.79, implying 8.2% upside from current levels. Seasonally, the next 20 trading days have averaged a -1.1% return over 5 years, rising in 3 of those years, a mixed signal worth noting alongside the GekkoIndex's five-day change of -1.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $43.24200-day averageGekko Fair Value $59.34
Key stats
- Market cap
- $192.0B
- P/E ratio
- 10.3
- Forward P/E
- 12.8
- EPS, TTM
- $4.20
- Revenue, TTM
- $329.4B
- Profit margin
- 35.3%
- Dividend yield
- 4.16%
- Beta
- 0.34
- Volume
- 10.30M avg 9.72M
- 1-year return
- −25.7%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±6.3%
- 50-day average
- $46.90
- 200-day average
- $46.15
- Next earnings
- Nov 4
- Shares outstanding
- 3.34B
Novo Nordisk swing-trade checklist
Novo Nordisk scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $43.24 sits between the 50-day ($46.90) and 200-day ($46.15) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.7, Accumulation
Reading 64.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
27.1% below
Price is 27.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−1.1% on average
From this point in the calendar, the next 20 trading days averaged −1.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Novo Nordisk stock chart and price history
Novo Nordisk closed at $43.24 on Sep 18, 2026, −25.7% over the past year, inside a 52-week range of $35.12 to $64.16.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.0%
- 3 months
- +0.1%
- 6 months
- +16.6%
- 1 year
- −25.7%
The full NVO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NVO in Gekko
Follow Novo Nordisk through every session
Put NVO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NVO in GekkoFree for 7 days. No credit card required.
About Novo Nordisk
Novo Nordisk makes and sells medicines to patients around the world, reaching markets in Europe, the Middle East, Africa, several Asian markets such as Mainland China, Hong Kong and Taiwan, and North America. Its name is most tied to diabetes and obesity treatment, though it also supplies medicines for heart-related conditions and for a set of rare diseases.
Its work is divided into two units. One handles diabetes and obesity, plus cardiovascular care and some newer treatment areas, while the other focuses on rare blood conditions, uncommon hormonal disorders and hormone replacement therapy. Alongside its drugs, the company builds related hardware like insulin pens, growth hormone pens and needles for injections, and offers digital aids for people managing diabetes, among them connected pens and an app called Dose Check that helps with dosing decisions. It has also teamed up with other organizations, working alongside UNICEF on reducing childhood obesity and with Valo Health on identifying new drug candidates for cardiometabolic disease.
The company traces back to 1923 and runs its headquarters out of Bagsvaerd, Denmark. Its stock can be found under the ticker NVO.
- Sector
- Health technology
- Website
- novonordisk.com
Novo Nordisk GekkoIndex: the smart money zone
Novo Nordisk’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.7, in the Accumulation zone, down 1 point over five sessions.
64.7Accumulation
Down 1 point over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 78 | +0.2% | +1.2% | ||
| Accumulation (current zone) | 250 | −0.2% | −2.0% | ||
| Neutral | 256 | −1.4% | −3.3% | ||
| Distribution | 31 | +0.5% | −8.2% | ||
| Selling | 0 | Not available | |||
Average NVO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the NVO price, zone by zone.Track NVO in Gekko
Is Novo Nordisk stock overvalued? Gekko Fair Value
Novo Nordisk trades 27.1% below Gekko Fair Value of $59.34, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Novo Nordisk shares are worth, recalculated every trading day.
$59.34
Gekko Fair Value, Sep 19, 2026
27.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open NVO in Gekko
Novo Nordisk insider and Congress trading
No open-market insider purchases were filed for Novo Nordisk, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Scott Mr Franklin House, FL, purchase | $1,001 - $15,000 | Sep 18 traded Aug 26 |
From congressional disclosures, which report amounts as ranges.
Hedge funds and billionaires quarter ended Dec 31
1of the funds Gekko tracks holds NVO.
1added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Novo Nordisk earnings: next date and track record
Novo Nordisk reports on Nov 4, 2026 (45 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 4, 2026
45 days away
- EPS estimate
- $0.80
- Revenue estimate
- $11.22B
6 of 8reports beat the EPS estimate
±5.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.96 est $0.82 | $12.13B est $10.89B | +3.8% |
| May 6, 2026 | $6.63 est $6.96 | $11.02B est $10.86B | +2.1% |
| Feb 3, 2026 | $6.04 est $5.90 | — | −19.9% |
| Nov 5, 2025 | $1.02 est $0.77 | $11.78B est $12.37B | −3.6% |
| Aug 6, 2025 | $0.97 est $0.93 | $12.13B est $12.30B | +3.3% |
| May 7, 2025 | $0.92 est $0.92 | $11.49B est $11.94B | −2.2% |
| Feb 5, 2025 | $6.34 est $5.97 | $11.86B est $11.55B | +5.5% |
| Nov 6, 2024 | $6.12 est $5.92 | — | −2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Novo Nordisk stock forecast and analyst price targets
Analysts’ average 12-month price target for Novo Nordisk is $46.79, +8.2% from the last close, from 6 firms rating the stock in the last 90 days.
$46.79consensus 12-month target, +8.2% from the last close
Now $43.24Avg $46.79
Low $40High $47
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | BMO Capital | $47 | +8.7% |
| Sep 11 | Morgan Stanley | $40 | −7.5% |
| Aug 17 | BMO Capital | $47 | +8.7% |
| Aug 12 | BMO Capital | $47 | +8.7% |
| Aug 11 | Berenberg Bank | $47 | +8.7% |
−2.0%average 20-day move after past Accumulation readings
−1.1%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Novo Nordisk seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Novo Nordisk averaged −1.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.3% | 0 of 5 |
| Next 10 trading days | −4.4% | 1 of 5 |
| Next 15 trading days | −3.6% | 1 of 5 |
| Next 20 trading days | −1.1% | 3 of 5 |
| Next 30 trading days | −2.6% | 3 of 5 |
For scale, NVO’s typical 20-trading-day move in either direction is about 6.3%.
Novo Nordisk market cap and key statistics
Novo Nordisk’s market cap is $192.0B, with a P/E ratio of 10.3 and revenue of $329.4B over the last twelve months.
Valuation
- Market cap
- $192.0B
- P/E ratio
- 10.3
- Forward P/E
- 12.8
- EPS, TTM
- $4.20
- Gekko Fair Value
- $59.34
Trading
- Volume
- 10.30M
- Avg volume, 20 days
- 9.72M
- 52-week high
- $64.16
- 52-week low
- $35.12
- Shares outstanding
- 3.34B
Financials
- Revenue, TTM
- $329.4B
- Profit margin
- 35.3%
- Return on equity
- 59.8%
- Quarterly earnings growth, YoY
- −20.6%
Risk and income
- Beta
- 0.34
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±6.3%
- Dividend yield
- 4.16%
Novo Nordisk stock news this week
6 headlines about Novo Nordisk from the past week, newest first, each linking to the publisher.
- Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European UnionZacks Investment Research, Sep 18
- 40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"Schwab Network, Sep 18
- EMA Committee Endorses Novo Nordisk's Hemophilia A TherapyBenzinga, Sep 17
- Novo Expands AI Push With Anthropic Deal to Accelerate Drug DiscoveryZacks Investment Research, Sep 17
- Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?Zacks Investment Research, Sep 17
- Novo, Orbis sign up to $1.4 billion deal to develop oral drugsReuters, Sep 17
Novo Nordisk stock FAQ
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $192.0B at the Sep 18, 2026 close of $43.24, with 3.34B shares outstanding. The shares trade on a P/E ratio of 10.3.
What is the Novo Nordisk stock forecast?
The consensus analyst 12-month price target for Novo Nordisk is $46.79, +8.2% from the last close. Of the 6 firms that rated the stock in the last 90 days, 0 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Novo Nordisk stock overvalued or undervalued?
On Gekko’s estimate Novo Nordisk is undervalued: the Sep 18, 2026 close of $43.24 is 27.1% below Gekko Fair Value of $59.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Novo Nordisk report earnings next?
Novo Nordisk is expected to report on Nov 4, 2026 (45 days away). Analysts expect earnings of $0.80 per share on revenue of $11.22B. Novo Nordisk beat the earnings estimate in 6 of its last 8 reports, moving 5.3% on average across the report.
What is Novo Nordisk’s 52-week high and low?
Novo Nordisk’s 52-week high is $64.16 and its 52-week low is $35.12; it closed at $43.24 on Sep 18, 2026, −25.7% over the past year.
Is Novo Nordisk stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Novo Nordisk the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.